Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma

IF 5.6 2区医学 Q1 UROLOGY & NEPHROLOGY European urology focus Pub Date : 2024-12-01 DOI:10.1016/j.euf.2025.01.003

Kevin K. Zarrabi , Ulka Vaishampayan , Pedro C. Barata

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Nivolumab联合Ipilimumab加活菌补充治疗转移性肾细胞癌增强免疫原性

生态失调可能会阻碍有效的肿瘤免疫，降低诸如免疫检查点阻断（ICB）等治疗肾细胞癌（RCC）的疗效。CBM588是一种含有活丁酸梭菌的产品，在缓解率和无进展生存期方面显示出提高ICB治疗转移性RCC有效性的希望。为了证实这些发现，进一步的研究应该考虑饮食和微生物组组成等因素，并包括患者选择的预测性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.

期刊最新文献

Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial. Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy. ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy. A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials.